Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311152 | 0.89 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL2309011 | 0.87 | PTGDR2 (0.64) | PTGDR2TBXA2RPTGDRAKR1B10AKR1B1 | |
| SCHEMBL2311145 | 0.86 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRKDM4EMEN1 | |
| SCHEMBL2312821 | 0.85 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRKDM4EMEN1 | |
| SCHEMBL2312766 | 0.85 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDRKDM4EMEN1 | |
| SCHEMBL2313009 | 0.83 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRAKR1B10AKR1B1 | |
| SCHEMBL2311998 | 0.83 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRKDM4EMEN1 | |
| SCHEMBL2309325 | 0.83 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRKDM4EMEN1 | |
| SCHEMBL2308286 | 0.82 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRAKR1B10AKR1B1 | |
| SCHEMBL2309861 | 0.81 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | claimed |
| EP-1833791-B1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-03 | — | — | EP | claimed |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | claimed |
| EP-1833791-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | claimed |
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-1833791-B1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1833791-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, CRHR2, GRK2 | PTGDR2 36/4885TBXA2R 9/4885PTGDR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.